Back to Search Start Over

14-3-3γ mediates the long-term inhibition of peripheral kappa opioid receptor antinociceptive signaling by norbinaltorphimine.

Authors :
Wedemeyer MJ
Jennings EM
Smith HR
Chavera TS
Jamshidi RJ
Berg KA
Clarke WP
Source :
Neuropharmacology [Neuropharmacology] 2022 Dec 01; Vol. 220, pp. 109251. Date of Electronic Publication: 2022 Sep 17.
Publication Year :
2022

Abstract

Long-term inhibition of kappa opioid receptor (KOR) signaling in peripheral pain-sensing neurons is a potential obstacle for development of peripherally-restricted KOR agonists that produce analgesia. Such a long-term inhibitory mechanism is invoked from activation of c-Jun N-terminal kinase (JNK) that follows a single injection of the KOR antagonist norbinaltorphimine (norBNI). This effect requires protein synthesis of an unknown mediator in peripheral pain-sensing neurons. Using 2D difference gel electrophoresis with tandem mass spectrometry, we have identified that the scaffolding protein 14-3-3γ is upregulated in peripheral sensory neurons following activation of JNK with norBNI. Knockdown of 14-3-3γ by siRNA eliminates the long-term reduction in KOR-mediated cAMP signaling by norBNI in peripheral sensory neurons in culture. Similarly, knockdown of 14-3-3γ in the rat hind paw abolished the norBNI-mediated long-term reduction in peripheral KOR-mediated antinociception. Further, overexpression of 14-3-3γ in KOR expressing CHO cells prevented KOR-mediated inhibition of cAMP signaling. These long-term effects are selective for KOR as heterologous regulation of other receptor systems was not observed. These data suggest that 14-3-3γ is both necessary and sufficient for the long-term inhibition of KOR by norBNI in peripheral sensory neurons.<br />Competing Interests: Conflicts of interest Authors report no conflict of interest.<br /> (Copyright © 2022 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1873-7064
Volume :
220
Database :
MEDLINE
Journal :
Neuropharmacology
Publication Type :
Academic Journal
Accession number :
36126728
Full Text :
https://doi.org/10.1016/j.neuropharm.2022.109251